CSIMarket


Reshape Lifesciences Inc   (RSLS)
Other Ticker:  
 


 

Reshape Lifesciences Inc

RSLS's Financial Statements and Analysis



Reshape Lifesciences Inc narrowed first quarter of 2024 net loss per share of $-0.09 compare to net loss per share of $-1.56 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.11 realized in previous quarter.


first quarter of 2024
Earnings Per Share Revenues
$ -0.09 $  2 Mill
$+1.47     Unch.     -15 %



Reshape Lifesciences Inc 's Revenue fell by -15 % in first quarter of 2024 (Mar 31 2024) year on year, to $2 million and advanced by 1.67 % sequentially.


Reshape Lifesciences Inc is

More on RSLS's Income Statement



Reshape Lifesciences Inc in the first quarter of 2024 recorded net loss of $-2.193 million, an improvement compare to net loss of $-2.662 million in I. Quarter a year ago.

Sequentially net loss advanced

More on RSLS's Growth

Reshape Lifesciences Inc Inventories
Inventories declined by -0.74 % to $3.47 million from I. Quarter a year ago, sequentially inventories fell by -7.32 %. In Mar 31 2024 company's net cash and cash equivalents decreased by $-2 million


Reshape Lifesciences Inc does not pay out common stock dividend.

In trailing twelve-month period Reshape Lifesciences Inc payed $ -0.60 cash per share, on a free-cash flow basis .

Book value fell by -82.71 % sequentially to $0.19 per share, -40.19% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.19 per share from $ 1.12.

Company issued 17.50 million shares or 293.46 % in Mar 31 2024.


More on RSLS's Dividends

 Market Capitalization (Millions) 5
 Shares Outstanding (Millions) 23
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Reshape Lifesciences Inc does not pay out common stock dividend.

In trailing twelve-month period Reshape Lifesciences Inc had negative $ -0.60 cash flow per share, on a free-cash flow basis .

Book value fell by -82.71 % sequentially to $0.19 per share, -40.19% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.19 per share from $ 1.12.

Company issued 17.50 million shares or 293.46 % in Mar 31 2024.


More on RSLS's Balance Sheets

 Market Capitalization (Millions) 5
 Shares Outstanding (Millions) 23
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Reshape Lifesciences Inc Earnings

Financial Challenges Persist for Reshape Lifesciences Inc as Revenue Softens



Reshape Lifesciences Inc, a medical device company specializing in weight loss solutions, recently released its financial results for the January to March 31, 2024 fiscal interval. While the company managed to trim its losses and implement a cost reduction plan, it still faces some financial challenges. This article delves into the implications of the financial figures on Reshape Lifesciences and discusses the company's potential turnaround.
Trimming Losses and Decreasing Revenue:
During the January to March 31, 2024 fiscal interval, Reshape Lifesciences Inc successfully reduced its losses, with the loss per share standing at $-0.09, compared to $-1.56 in the same reporting period a year ag...

Revenue Plummets at Reshape Lifesciences Inc Amid Fiscal Quarter Ending December 31, 2023

Reshape Lifesciences Inc, a medical equipment and supplies company, recently reported its financial results for the fourth quarter of 2023. The company showed improvement in its earnings per share, with a decrease in the loss per share from $-0.86 a year ago to $-0.11 per share. Additionally, the EPS improved from $-1.02 per share in the prior quarter.
In terms of revenue, Reshape Lifesciences Inc experienced a decline of -38.521% to $1.91 million compared to $3.11 million in the same quarter a year ago. Sequentially, the revenue also deteriorated by -11.276% from $2.16 million. Despite this decline, the company reported a net deficit of $-1.698 million, a significant improvement from the deficit of $-16...

Revolutionary Medical Equipment & Supplies Firm: Dwindling Revenues in Q3 2023 Raises Eyebrows

Reshape Lifesciences Inc, a medical equipment and supplies company, recently reported its financial results for the most recent fiscal period. The company experienced a rise in losses due to weak orders, causing a net deficit per share to increase from $-0.52 to $-1.02. Additionally, revenue dropped by -22.981% to $2.16 million compared to $2.80 million in the previous year.
The decline in revenue for Reshape Lifesciences Inc is in stark contrast to the on average revenue gain recorded by the Medical Equipment and Supplies sector. While the sector as a whole saw an increase in revenue, Reshape Lifesciences Inc suffered a slump in their top-line. This disparity may raise concerns about the company's abili...

Reshape Lifesciences Inc Reports Gloomy -24.136% Drop in Revenue, Indicating Challenging Market Environment

Financial news report:
Weak demand caused an increase in losses for Reshape Lifesciences Inc in the financial time-frame ending June 30, 2023. The company's shortfall per share rose to $-1.08 from $-0.50, while revenue fell by -24.136% to $2.19 million from $2.89 million a year before. This decline in revenue can be attributed to the challenging market environment faced by Reshape Lifesciences Inc.
In contrast to RSLS's scenario, the overall Medical Equipment and Supplies industry posted a revenue growth of 4.21% relative to the corresponding period a year ago in the second quarter of 2023. This indicates that the industry as a whole has been more successful in generating revenue compared to Reshape ...

Reshape Lifesciences Inc Suffers Intensified Losses, Accumulating a $41 Million Net Loss and Alarming -246.1% ROI in Q1 2023, Signaling Investor Concern

Reshape Lifesciences Inc, a healthcare company, has experienced a tough financial year, recording a cumulative net loss of $-41 million during the 12 months ending in the first quarter of 2023. This translates into a negative return on investment (ROI) of -246.1%, which is concerning for its investors and shareholders.
In comparison to other healthcare companies, Reshape Lifesciences Inc fell behind with 744 other companies reporting a higher return on investment. Despite this, there has been a slight improvement in their overall ranking for ROI in the Mar 31 2023 quarter. This progress indicates that the company is taking step...


Date modified: 2024-05-16T12:35:00+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com